Regeneron Pharmaceuticals has received European Commission approval for its drug Ordspono (odronextamab) for treating adult patients with relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma. This approval is a significant win for the company, following a setback in the US. However, the company faces challenges in the US market as it works to overcome regulatory hurdles for its oncology drugs.